Montag A & Associates Inc. Invests $236,000 in Opko Health Inc. (OPK)

Montag A & Associates Inc. acquired a new stake in Opko Health Inc. (NASDAQ:OPK) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 68,290 shares of the biotechnology company’s stock, valued at approximately $236,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Meeder Asset Management Inc. raised its position in Opko Health by 1,290.1% during the third quarter. Meeder Asset Management Inc. now owns 31,611 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 29,337 shares during the last quarter. SG Americas Securities LLC acquired a new position in Opko Health during the second quarter worth about $136,000. North Star Investment Management Corp. acquired a new position in Opko Health during the second quarter worth about $141,000. RPg Family Wealth Advisory LLC raised its position in Opko Health by 74.3% during the second quarter. RPg Family Wealth Advisory LLC now owns 31,080 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 13,250 shares during the last quarter. Finally, Xact Kapitalforvaltning AB raised its position in Opko Health by 58.2% during the first quarter. Xact Kapitalforvaltning AB now owns 57,921 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 21,300 shares during the last quarter. Hedge funds and other institutional investors own 24.87% of the company’s stock.

In other news, CEO Phillip Md Et Al Frost purchased 5,000 shares of the stock in a transaction dated Tuesday, August 28th. The stock was acquired at an average cost of $5.80 per share, for a total transaction of $29,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $17,799,915.80. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have bought 45,000 shares of company stock valued at $257,600. Insiders own 42.74% of the company’s stock.

A number of brokerages have issued reports on OPK. BidaskClub upgraded shares of Opko Health from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 24th. ValuEngine upgraded shares of Opko Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 2nd. Cantor Fitzgerald restated a “buy” rating and set a $20.00 target price on shares of Opko Health in a research report on Tuesday, August 7th. Finally, Barrington Research reiterated a “buy” rating and set a $7.00 price target on shares of Opko Health in a report on Monday, November 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $9.69.

Shares of NASDAQ OPK opened at $3.56 on Friday. Opko Health Inc. has a 12 month low of $2.66 and a 12 month high of $6.40. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.91 and a quick ratio of 0.90.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $250.00 million during the quarter, compared to the consensus estimate of $264.04 million. Opko Health had a negative net margin of 30.24% and a negative return on equity of 8.68%. The company’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.08) earnings per share. As a group, sell-side analysts expect that Opko Health Inc. will post -0.23 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/11/17/montag-a-associates-inc-invests-236000-in-opko-health-inc-opk.html.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Read More: Hedge Funds Explained

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit